News & Events

Other Events. On May 21, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule I thereto, pursuant to which the Company agreed to issue and sell, in an underwritten offering (the “Offering”), an aggregate of 16,778,524 shares of its common stock, par value $0.0001 per share (the “Shares”) at a public offering price…

Other Events. On May 21, 2026, the Company announced an update from the Phase 2 NEXICART-2 NXC-201 clinical trial, including that all four MRD-negative relapsed/refractory AL Amyloidosis patients announced by the Company at the ASH 2025 have converted to CR. Of the first 20 patients in NEXICART-2, all MRD-negative patients have converted to CR, increasing the CR rate to 95% (19/20). No relapses have been observed to date for patients who have reached CR, and all CRs were reached within one ye…

Entry into a Material Definitive Agreement. On March 25, 2026, Immix Biopharma, Inc., a Delaware corporation (the “Company”) and Citizens JMP Securities, LLC entered into Amendment No. 1 (“Amendment No. 1”) to that certain At The Market Offering Agreement, dated June 3, 2025 (the “Sales Agreement”), pursuant to which the Company may offer and sell, from time to time, at its option, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), through Citizens JMP Sec…

Entry into a Material Definitive Agreement. Underwritten Registered Offering On December 7, 2025, Immix Biopharma, Inc., a Delaware corporation (the “ Company ”), entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC, as representative of the several underwriters named in Schedule 1 thereto (the “ Underwriters ”), relating to the issuance and sale (the “ Offering ”) of 19,117,646 shares of its common stock, par value $0.0001 per share (the “ Sha…

Unregistered Sales of Equity Securities. The information contained in

Entry into a Material Definitive Agreement. On September 5, 2025, Immix Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) and a Registration Rights Agreement (the “Registration Rights Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers in a private placement transaction (the “Private Placement”) (i) 3,831,216 shares (the “Shares”) of the Company’s common stock, p…

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective September 8, 2025 and in connection with the closing of the Private Placement, the Board of Directors (the “Board”) of the Company appointed Nancy Chang, Ph.D. as a member of the Board. Dr. Chang will serve as a director for a term continuing until the Company’s 2026 annual meeting of stockholders and until her successor has been duly ele…

Entry into a Material Definitive Agreement. On June 3, 2025, Immix Biopharma, Inc. (the “Company”) entered into an At The Market Offering Agreement (the “Agreement”) with Citizens JMP Securities, LLC (“Agent”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.0001 par value common stock (“Common Stock”), through the Agent as its sales agent. Pursuant to the Agreement, sales of the Common Stock, if any, will be made under the Company’s effec…